The company provides IT infrastructure services, software development, and wholesale trading of computer hardware and peripherals to small and medium enterprises.
The company operates in a highly fragmented and commoditized IT hardware trading and services market with no evidence of proprietary technology or high switching costs. While net margins appear high at 32%, the low cash conversion ratio suggests these may be accounting-driven rather than reflecting true economic pricing power.
Management has shifted focus from legacy industrial trading to AI and software, including a 2024 acquisition of a 51% stake in Moodscope AI. Capital is also deployed in unsecured loans to third parties and subsidiaries, which carries significant credit risk.
By 2029, the pivot to AI proved to be a superficial rebranding of a commodity hardware business. The massive unsecured loans to third parties, which lacked repayment schedules, eventually defaulted, wiping out the balance sheet. The high accounting margins never translated into cash, as the low conversion ratio signaled early on that the earnings were largely illusory. When the related-party transactions and regulatory lapses finally drew scrutiny, the stock collapsed as investors realized they owned a capital-depleting loan book disguised as a technology firm.
RichFakir rates Shradha AI Technologies Ltd's business quality as poor — 39/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Shradha AI Technologies Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shradha AI Technologies Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shradha AI Technologies Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →